In short
Deucrictibant is an investigational drug being studied for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. Clinical trials are evaluating deucrictibant as both a preventive medication and an on-demand treatment for acute HAE attacks. This article summarizes key information about ongoing deucrictibant clinical trials for patients with HAE.
At a glance
- Drug Name
- Deucrictibant (also known as PHA-022121, PHA121, PHVS416)
- Condition
- Hereditary Angioedema (HAE) Types I and II
- Administration
- Oral (extended-release tablets or soft capsules)
- Trial Types
- Phase 2 and 3 studies for both prophylaxis and on-demand treatment
- Key Outcomes
- Number and severity of HAE attacks, time to symptom relief, quality of life measures
- Safety Assessments
- Adverse events, vital signs, laboratory tests, electrocardiograms
- Patient Population
- Adolescents and adults (ages 12 and up) with HAE types I or II
What is Deucrictibant?
Deucrictibant is a new medication being developed to treat hereditary angioedema (HAE). It is also known by other names such as PHA-022121, PHA121, and PHVS416. Hereditary angioedema is a rare genetic condition that causes sudden, severe swelling in various parts of the body, including the skin, intestines, and airways. These swelling episodes, called "attacks," can be painful, disfiguring, and even life-threatening if they affect the throat.
What Conditions Does Deucrictibant Treat?
Deucrictibant is specifically designed to treat hereditary angioedema types I and II. These types are caused by a deficiency or dysfunction of a protein called C1 inhibitor. The medication is being studied for two main purposes:
- Acute treatment: To treat HAE attacks when they occur
- Prophylaxis: To prevent HAE attacks from happening
This dual approach aims to provide comprehensive management for patients with HAE, potentially improving their quality of life by both treating and preventing angioedema attacks.
How is Deucrictibant Administered?
One of the most promising aspects of deucrictibant is its method of administration. Unlike many current HAE treatments that require injections or intravenous infusions, deucrictibant is taken orally. It comes in two forms:
- Soft capsules: Used for acute treatment of HAE attacks
- Extended-release tablets: Used for long-term prevention of HAE attacks
This oral administration could potentially make treatment more convenient and less invasive for patients with HAE.
Ongoing Clinical Trials
Deucrictibant is currently being studied in several clinical trials to evaluate its safety and effectiveness. These trials include:
- CHAPTER-1 (NCT06679881): A long-term study evaluating the safety and efficacy of daily deucrictibant for preventing HAE attacks in adolescents and adults.
- CHAPTER-2 (NCT06669754): A study comparing deucrictibant to placebo for preventing HAE attacks over 24 weeks.
- CHAPTER-3 (NCT06343779): A study evaluating deucrictibant for on-demand treatment of HAE attacks.
- RAPIDe-1 (NCT04618211): A dose-ranging study for acute treatment of HAE attacks.
- RAPIDe-2 (NCT05396105): An extension study for long-term evaluation of deucrictibant in acute treatment of HAE attacks.
- CHAPTER-1 (NCT05047185): A dose-ranging study for prevention of HAE attacks.
Potential Benefits
Based on the ongoing clinical trials, deucrictibant shows promise in several areas:
- Rapid relief: Studies are measuring how quickly symptoms improve after taking deucrictibant, with some trials looking at relief as soon as 4 hours after treatment.
- Attack prevention: Long-term studies are evaluating how well deucrictibant can reduce the frequency of HAE attacks.
- Quality of life improvement: Researchers are using various questionnaires to assess how deucrictibant affects patients' overall well-being and ability to carry out daily activities.
- Convenience: The oral administration could make it easier for patients to take their medication regularly, potentially improving treatment adherence.
Safety and Side Effects
As with any new medication, safety is a primary concern in the deucrictibant clinical trials. Researchers are closely monitoring for any adverse effects, including:
- Changes in heart rate, blood pressure, and body temperature
- Alterations in blood and urine tests
- Changes in electrocardiogram (ECG) readings
- Any other unexpected side effects
It's important to note that the full safety profile of deucrictibant will not be known until all clinical trials are completed and the data is thoroughly analyzed. Patients interested in participating in clinical trials or learning more about deucrictibant should discuss this with their healthcare provider.